{
    "ticker": "AARD",
    "name": "Aardvark Therapeutics, Inc. Common Stock",
    "market": "stocks",
    "locale": "us",
    "primary_exchange": "XNAS",
    "type": "CS",
    "active": true,
    "currency_name": "usd",
    "cik": "0001774857",
    "composite_figi": "BBG01223DLB2",
    "share_class_figi": "BBG01223DLC1",
    "market_cap": 211919176.07,
    "description": "Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.",
    "ticker_root": "AARD",
    "homepage_url": "https://www.aardvarktherapeutics.com",
    "list_date": "2025-02-13",
    "branding": {
        "logo_url": "https://api.polygon.io/v1/reference/company-branding/YWFyZHZhcmt0aGVyYXBldXRpY3MuY29t/images/2025-03-20_logo.png",
        "icon_url": "https://api.polygon.io/v1/reference/company-branding/YWFyZHZhcmt0aGVyYXBldXRpY3MuY29t/images/2025-03-20_icon.jpeg"
    },
    "share_class_shares_outstanding": 21380000,
    "weighted_shares_outstanding": 21384377,
    "round_lot": 100
}